AbbVie, Genmab say epcoritamab plus R-CHOP cuts risk of progression or death 51% in Phase 3 DLBCL trial

Bitget2026/10/05 18:56

AbbVie disclosed positive topline Phase 3 results for epcoritamab combined with R-CHOP in newly diagnosed diffuse large B-cell lymphoma. The study showed a clear improvement in delaying disease worsening versus standard R-CHOP, supporting a potential shift in frontline care. Safety in the combination was broadly consistent with known profiles for the individual medicines, with no new concerns highlighted. Results have not yet been presented; the companies plan to submit the data to a future medical meeting. AbbVie plans to engage regulators globally on next steps; the epcoritamab-R-CHOP regimen remains investigational for this setting. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610051454PR_NEWS_USPR_____CG63080) on October 05, 2026, and is solely responsible for the information contained therein.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

AbbVie disclosed positive topline Phase 3 results for epcoritamab combined with R-CHOP in newly diagnosed diffuse large B-cell lymphoma.
The study showed a clear improvement in delaying disease worsening versus standard R-CHOP, supporting a potential shift in frontline care.
Safety in the combination was broadly consistent with known profiles for the individual medicines, with no new concerns highlighted.
Results have not yet been presented; the companies plan to submit the data to a future medical meeting.
AbbVie plans to engage regulators globally on next steps; the epcoritamab-R-CHOP regimen remains investigational for this setting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610051454PR_NEWS_USPR_____CG63080) on October 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.

华尔街见闻•2026/11/09 10:26